Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 542 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo patch Clear all
Completed Phase 1Phase 2 Interventional

To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris

NCT00050661
View directory record Official record
Conditions
Psoriasis
Interventions
Daclizumab, NB-UVB
Drug · Device
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 19, 2026, 5:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy

NCT02223182
View directory record Official record
Conditions
Food Allergy
Interventions
Viaskin Milk 150 mcg, Viaskin Milk 300 mcg, Viaskin Milk 500 mcg, Viaskin Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
2 Years to 17 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
12
States / cities
Little Rock, Arkansas • San Diego, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 19, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis

NCT04992546
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PRN473 (SAR444727), Placebo
Drug
Lead sponsor
Principia Biopharma, a Sanofi Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Long Beach, California • Los Angeles, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 19, 2026, 5:24 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Study of LUT017 Gel to Improve Healing of Skin Wounds After Removal of Benign Lesions in Healthy Adults

NCT07463378
View directory record Official record
Conditions
Wound Healing, Acute Skin Wounds
Interventions
LUT017,Topical BRAF inhibitor
Drug
Lead sponsor
Antoni Ribas
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 19, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

NCT01358578
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Placebo, secukinumab (AIN457), etanercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 19, 2026, 5:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The OBstetric Lidocaine Patch (OBLido) Trial

NCT03810235
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Transdermal Lidocaine Patch, Transdermal Hydrocolloid Placebo Patch
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 59 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 19, 2026, 5:24 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness

NCT04272255
View directory record Official record
Conditions
Motion Sickness
Interventions
scopolamine HBr, Transdermal Scopolamine
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 19, 2026, 5:24 PM EDT
Completed Early Phase 1 Interventional Results available

Oxytocin Effects on Cardiac Electrophysiology

NCT01780337
View directory record Official record
Conditions
Cardiac Arrhythmia
Interventions
Oxytocin, Saline
Drug · Other
Lead sponsor
William Whang
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 19, 2026, 5:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation

NCT02859142
View directory record Official record
Conditions
Smoking Cessation, Alcohol Drinking
Interventions
Chantix, Behavioral Counseling Sessions, NicodermCQ, Placebo
Drug · Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 85 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 19, 2026, 5:24 PM EDT
Terminated Phase 1 Interventional

Topical Calcipotriene Treatment for Breast Cancer Immunoprevention

NCT03596073
View directory record Official record
Conditions
Breast Cancer
Interventions
Topical Calcipotriene Ointment, Topical Vaseline
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 19, 2026, 5:24 PM EDT
Completed Phase 2 Interventional

Chemoprevention of Oral Premalignant Lesions

NCT00036283
View directory record Official record
Conditions
Precancerous Conditions
Interventions
Celecoxib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
7
States / cities
Farmington, Connecticut • Shreveport, Louisiana • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2008 · Synced Oct 19, 2026, 5:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging

NCT01664741
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Nicotine patch - transdermal, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 60 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 19, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Results available

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

NCT03185013
View directory record Official record
Conditions
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions
VGX-3100, Placebo, Electroporation (EP)
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
22
States / cities
Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 19, 2026, 5:24 PM EDT
Completed Not applicable Interventional Results available

Does Radiofrequency Ablation of the Articular Nerves of the Knee Prior to Total Knee Replacement Improve Pain Outcomes

NCT02746874
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee
Interventions
Radiofrequency Ablation (RFA), Simulated Radiofrequency Ablation (RFA)
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 19, 2026, 5:24 PM EDT
Active, not recruiting Phase 2 Interventional

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

NCT06299891
View directory record Official record
Conditions
Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions
Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo
Drug · Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Years to 28 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 5:24 PM EDT
Not yet recruiting Phase 4 Interventional

High-concentration Capsaicin Patch for the Prevention of Paclitaxel-induced Peripheral Neuropathy

NCT07834281
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Interventions
High Concentration Capsaicin Patch (HCCP), Placebo patch
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 19, 2026, 5:24 PM EDT
Recruiting Phase 3 Interventional

Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee

NCT04433572
View directory record Official record
Conditions
Peripheral Artery Disease, Critical Limb Ischemia
Interventions
Temsirolimus, Saline placebo
Drug
Lead sponsor
Mercator MedSystems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
2
States / cities
Houma, Louisiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 19, 2026, 5:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Use of Topical NSAID to Reduce Pain in Oral Lichen Planus and Oral Lichenoid Lesions.

NCT03509675
View directory record Official record
Conditions
Oral Lichen Planus, Oral Lichenoid Mucositis, Oral Lichenoid Reaction
Interventions
Ibuprofen suspension 5mg/100ml, Placebos
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 19, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Experimental and Commercial Air-Activated, Adhesive Backed Heat Patches

NCT01841801
View directory record Official record
Conditions
Effects of Heat, Tolerability, Adhesiveness, Dermal Irritation
Interventions
Thermal Adhesive Patch, Marketed Thermal Adhesive Patch, Placebo Patch
Device
Lead sponsor
Chattem, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Pinellas Park, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 19, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Smoking Environments on Craving and Smoking (CameraCue2.0)

NCT02551692
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Nicotine Patch, Varenicline, Placebo Nicotine Patch, Placebo Capsule
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 19, 2026, 5:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluate the Depth and Duration of Anesthesia

NCT00891163
View directory record Official record
Conditions
Pain
Interventions
Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine), Placebo Patch
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 1, 2009 · Synced Oct 19, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

NCT00775463
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
treprostinil diethanolamine, placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 19, 2026, 5:24 PM EDT
Completed Phase 3 Interventional

Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Soft Tissue Injuries (TAPED)

NCT00931866
View directory record Official record
Conditions
Acute Pain, Soft Tissue Injury
Interventions
Diclofenac Sodium, Matching Placebo Patch
Drug
Lead sponsor
Cerimon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 19, 2026, 5:24 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

HIV-1 and Brain Interaction on Smoking Comorbidity

NCT03308331
View directory record Official record
Conditions
Smoking
Interventions
Tobacco smoking and nicotine patch
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 19, 2026, 5:24 PM EDT